Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Accumulated Expenses (2023 - 2026)

Beta Bionics' Accumulated Expenses history spans 4 years, with the latest figure at $17.3 million for Q1 2026.

  • On a quarterly basis, Accumulated Expenses rose 64.02% to $17.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $17.3 million, a 64.02% increase, with the full-year FY2025 number at $22.4 million, up 41.72% from a year prior.
  • Accumulated Expenses hit $17.3 million in Q1 2026 for Beta Bionics, down from $22.4 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for BBNX hit a ceiling of $22.4 million in Q4 2025 and a floor of $8.1 million in Q4 2023.
  • Historically, Accumulated Expenses has averaged $15.0 million across 4 years, with a median of $15.8 million in 2024.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 94.73% in 2024 and later skyrocketed 41.72% in 2025.
  • Tracing BBNX's Accumulated Expenses over 4 years: stood at $8.1 million in 2023, then skyrocketed by 94.73% to $15.8 million in 2024, then soared by 41.72% to $22.4 million in 2025, then decreased by 22.75% to $17.3 million in 2026.
  • Business Quant data shows Accumulated Expenses for BBNX at $17.3 million in Q1 2026, $22.4 million in Q4 2025, and $17.6 million in Q3 2025.